Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine, 483 Expo-ro, Yusung-gu, Daejeon 305-811, Republic of Korea.
J Inflamm (Lond). 2012 Oct 30;9(1):41. doi: 10.1186/1476-9255-9-41.
Dianthus superbus has long been used as a herbal medicine in Asia and as an anti-inflammatory agent. In this study, we evaluated the anti-inflammatory effects of Dianthus superbus fructus ethanolic extract (DSE) on Th2-type cytokines, eosinophil infiltration, and other factors in an ovalbumin (OVA)-induced murine asthma model. To study the possible mechanism of the anti-inflammatory effect of DSE, we also evaluated the expression of inducible nitric oxide synthase (iNOS) in the respiratory tract.
Mice were sensitized on days 0 and 14 by intraperitoneal injection of OVA. On days 21, 22 and 23 after initial sensitization, mice received an airway challenge with OVA for 1 h using an ultrasonic nebulizer. DSE was applied 1 h prior to OVA challenge. Mice were administered DSE orally at doses of 100 mg/kg or 200 mg/kg once daily from day 18 to 23. Bronchoalveolar lavage fluid (BALF) was collected 48 h after the final OVA challenge. Levels of interleukin (IL)-4, IL-13 and eotaxin in BALF were measured using enzyme-linked immunosorbent assays (ELISAs). Lung tissue sections were stained with hematoxylin and eosin for assessment of cell infiltration and mucus production with periodic acid shift staining, in conjunction with ELISA and western blot analyses for iNOS expression.
DSE significantly reduced the levels of IL-4, IL-13, eotaxin, and immunoglobulin (Ig) E, number of inflammatory cells in BALF, and inflammatory cell infiltration and mucus production in the respiratory tract. DSE also attenuated the overexpression of iNOS protein induced by OVA challenge.
Our results suggest that DSE effectively protects against allergic airway inflammation by downregulating of iNOS expression and that DSE has potential as a therapeutic agent for allergic asthma.
香石竹作为一种草药在亚洲被长期使用,具有抗炎作用。在这项研究中,我们评估了香石竹果实乙醇提取物(DSE)对卵清蛋白(OVA)诱导的小鼠哮喘模型中 Th2 型细胞因子、嗜酸性粒细胞浸润和其他因素的抗炎作用。为了研究 DSE 抗炎作用的可能机制,我们还评估了呼吸道中诱导型一氧化氮合酶(iNOS)的表达。
在第 0 天和第 14 天,通过腹腔注射 OVA 对小鼠进行致敏。初次致敏后第 21、22 和 23 天,使用超声雾化器对小鼠进行 OVA 气道挑战 1 小时。在 OVA 挑战前 1 小时给予 DSE。从第 18 天到第 23 天,DSE 每天口服 100mg/kg 或 200mg/kg 一次。在最后一次 OVA 挑战后 48 小时收集支气管肺泡灌洗液(BALF)。使用酶联免疫吸附试验(ELISA)测量 BALF 中白细胞介素(IL)-4、IL-13 和嗜酸性粒细胞趋化因子水平。用苏木精和伊红对肺组织切片进行染色,结合 ELISA 和 Western blot 分析评估 iNOS 表达,以评估细胞浸润和过碘酸希夫(PAS)染色的黏液产生。
DSE 显著降低了 BALF 中的 IL-4、IL-13、嗜酸性粒细胞趋化因子和免疫球蛋白(Ig)E 水平、BALF 中的炎症细胞数量、呼吸道中的炎症细胞浸润和黏液产生。DSE 还减弱了 OVA 挑战引起的 iNOS 蛋白的过表达。
我们的研究结果表明,DSE 通过下调 iNOS 表达有效保护气道免受过敏炎症反应,DSE 有望成为治疗过敏性哮喘的药物。